Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Rituximab 22Lenalidomide 13orelabrutinib 12obinutuzumab 11Cyclophosphamide 9zanubrutinib 8fludarabine 7venetoclax 5Magnetic Resonance Spectroscopy 5Bendamustine Hydrochloride 5pirtobrutinib 4Specimen Handling 4Biopsy 4fludarabine phosphate 3Whole-Body Irradiation 2Vincristine 2Stem Cell Transplantation 2Prednisone 2Mycophenolic Acid 2CT-P10 2Automobiles 2treosulfan 1tafasitamab 1polatuzumab vedotin 1pemigatinib 1loncastuximab tesirine 1ibrutinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell, Marginal Zone × Maintenance × Clear all
NCT07372365 2026-01-28

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
23 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡